Larimar Therapeutics, Inc.

NasdaqGM LRMR

Larimar Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 56,266,890

Larimar Therapeutics, Inc. Shares (Diluted, Weighted) is 56,266,890 for the Trailing 12 Months (TTM) ending September 30, 2024, a 44.56% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Larimar Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 38,923,438, a 101.56% change year over year.
Larimar Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 19,311,196, a 16.57% change year over year.
Larimar Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 16,566,347, a 51.31% change year over year.
Larimar Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 10,948,363, a 76.87% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGM: LRMR

Larimar Therapeutics, Inc.

CEO	Dr. Carole S. Ben-Maimon M.D.
IPO Date	June 19, 2014
Location	United States
Headquarters	Three Bala Plaza East
Employees	42
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Key trends

Past 5 years